Elafibranor


Dual peroxisome proliferator-activated receptor alpha/delta (PPARalpha/delta) agonist with additional PPARgamma activity

A first-in-class dual PPARalpha/delta agonist developed by Genfit for hepatic steatoinflammatory and cholestatic liver diseases, granted FDA accelerated approval in June 2024 as Iqirvo for the treatment of primary biliary cholangitis in adults with inadequate response or intolerance to ursodeoxycholic acid.

Abstract

Elafibranor (GFT505) is a synthetic phenoxyalkanoic acid derivative and dual agonist of the peroxisome proliferator-activated receptor alpha (PPARalpha) and peroxisome proliferator-activated receptor delta (PPARdelta), with additional lower-potency agonist activity at the peroxisome proliferator-activated receptor gamma (PPARgamma). The compound activates PPARalpha with an EC50 of approximately 45 nanomolar and PPARdelta with an EC50 of approximately 175 nanomolar, producing a composite pharmacological profile that modulates hepatic fatty acid beta-oxidation, triglyceride metabolism, high-density lipoprotein cholesterol, bile acid synthesis and transport, glucose homeostasis, and macrophage-mediated hepatic inflammation through coordinated transcriptional regulation at both receptor subtypes. Elafibranor and its principal active metabolite GFT1007, formed by hydrolysis of the parent compound, both contribute to the pharmacological activity. On June 10, 2024, the United States Food and Drug Administration granted accelerated approval to elafibranor (trade name Iqirvo, marketed by Ipsen) for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. European Union authorization followed in September 2024, and the United Kingdom National Institute for Health and Care Excellence (NICE) recommended elafibranor for National Health Service use in October 2024. Pharmacokinetics are characterized by high plasma protein binding (approximately 99.7 percent), a large apparent volume of distribution (approximately 4,731 liters), a long elimination half-life of the parent compound (approximately 60 to 70 hours), and metabolism of GFT1007 through CYP2C8, UGT1A3, and UGT2B7. The compound is contraindicated in decompensated cirrhosis and complete biliary obstruction and carries a warning for embryo-fetal toxicity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph